BI 836880

Drug Profile

BI 836880

Alternative Names: Anti-VEGF/Ang2 Nanobody®; Bi-specific Anti-VEGF/Ang2 Nanobody®

Latest Information Update: 03 May 2016

Price : $50

At a glance

  • Originator Ablynx
  • Developer Boehringer Ingelheim
  • Class Antineoplastics; Bispecific antibodies
  • Mechanism of Action Angiopoietin-2 inhibitors; Vascular endothelial growth factors inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 01 Apr 2016 Boehringer Ingelheim initiates a phase I trial in Solid tumours (Late-stage disease, Metastatic disease) in France (NCT02689505)
  • 26 Feb 2016 Boehringer Ingelheim plans a phase I trial in Solid tumours (Late-stage disease, Metastatic disease) in Spain and France (NCT02689505)
  • 01 Jan 2016 Phase-I clinical trials in Solid tumours (Late-stage disease, Metastatic disease) in Germany (IV) (NCT02674152)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top